Clinical Trial Update: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating carboplatin with or without APR-246 (eprenetapopt) for platinum-sensitive recurrent high-grade serous ovarian cancer with mutated p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer

Drugs mentioned

• APR-246 (eprenetapopt)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Aprea Therapeutics | Conditions: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-09-21